Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection

INTRODUCTION: Nivolumab demonstrated significant recurrence-free survival (RFS) gains versus ipilimumab in the CheckMate-238 trial, whereas the CA184-029 trial showed superior RFS gains for ipilimumab versus placebo. No head-to-head trial data were available to compare the efficacy of nivolumab to t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacoecon Open
Hlavní autoři: Batteson, Rachael, Hart, Rose, Hemstock, Matthew, Gooden, Kyna, Kotapati, Srividya, Roze, Stephane, Lee, Dawn, Amadi, Adenike
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2019
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248152/
https://ncbi.nlm.nih.gov/pubmed/31587138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-00181-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky